import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "cortagen-cardiac-bioregulator-peptide-research-guide",
  title: "Cortagen: The Cardiac Bioregulator Peptide Studied for Heart Tissue Protection",
  description:
    "A research overview of Cortagen — a synthetic tetrapeptide bioregulator derived from heart tissue, studied for cardioprotective, anti-apoptotic, and cardiac repair effects. Covers mechanism, research history, and protocol parameters.",
  category: "Compound Profiles",
  readMinutes: 8,
  publishedAt: "2026-06-17",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Cortagen is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Pro (alanine–glutamic acid–aspartic acid–proline), developed as part of the Russian bioregulator peptide research program led primarily by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Biogerontology. As a cytamine-class bioregulator, Cortagen is proposed to be tissue-specific to cardiac muscle — derived from heart tissue extract — with proposed applications in cardioprotection, post-ischemic repair, and cardiac aging research.",
    },
    {
      type: "paragraph",
      text: "The bioregulator peptide program spans several dozen compounds, each derived from specific organ or tissue sources. Cortagen occupies the cardiac niche within this framework, alongside more widely known cardiovascular peptides like Thymalin (immune/cardiac) and SS-31/elamipretide (mitochondria-targeted). For researchers studying peptide-mediated cardioprotection, Cortagen presents a distinct and underexplored mechanism profile.",
    },
    {
      type: "heading",
      text: "Background and Development",
    },
    {
      type: "paragraph",
      text: "The identification of Cortagen followed the broader Khavinson research program's pattern: isolation of active short peptide fractions from organ-specific tissue extracts (originally called cytamines), followed by determination of the minimal active sequence, and subsequent chemical synthesis of that sequence for research and pharmaceutical purposes. Cortagen's synthetic form was developed as a precise tetrapeptide for more standardized research use compared to the original complex cytamine extract preparations.",
    },
    {
      type: "paragraph",
      text: "Research interest in Cortagen has focused on two primary contexts: (1) post-ischemic cardioprotection — protecting cardiomyocytes from the cell death cascade following ischemia-reperfusion events; and (2) cardiac aging — the progressive loss of cardiomyocyte function and regenerative capacity observed with advancing age. Both areas connect to significant unmet needs in cardiovascular medicine and have motivated the published preclinical research.",
    },
    {
      type: "heading",
      text: "Proposed Mechanism of Action",
    },
    {
      type: "subheading",
      text: "Transcriptional Regulation and Gene Expression",
    },
    {
      type: "paragraph",
      text: "Like other bioregulator peptides in the Khavinson framework, Cortagen is proposed to modulate gene expression at the transcriptional level by interacting with DNA-histone complexes and chromatin structure. Published research suggests Cortagen may influence the expression of genes involved in cardiomyocyte survival, apoptosis regulation, and cellular repair. In aging cardiac tissue, altered expression of these genes correlates with progressive functional decline — positioning transcriptional modulators as a potential research tool for understanding and potentially modifying this process.",
    },
    {
      type: "subheading",
      text: "Anti-Apoptotic Signaling",
    },
    {
      type: "paragraph",
      text: "Several preclinical studies have reported that Cortagen administration is associated with reduced cardiomyocyte apoptosis in ischemia-reperfusion models. The proposed mechanism involves upregulation of Bcl-2 family anti-apoptotic proteins and downregulation of pro-apoptotic cascades (caspase activation) in cardiac tissue. Reduced cardiomyocyte loss after ischemic events is a central goal in cardioprotection research, given that mature cardiomyocytes have limited regenerative capacity.",
    },
    {
      type: "subheading",
      text: "Connective Tissue and Fibrosis Modulation",
    },
    {
      type: "paragraph",
      text: "Post-ischemic cardiac remodeling involves fibroblast activation and collagen deposition, which can impair cardiac function. Research has examined whether Cortagen modulates the fibrotic response in cardiac tissue following injury, with some studies reporting attenuated fibrosis markers in treated animals compared to controls. The proline residue in Cortagen's sequence (Ala-Glu-Asp-Pro) has been noted as potentially relevant here, as proline is a key structural component of collagen and a residue found in several regulatory peptide sequences.",
    },
    {
      type: "subheading",
      text: "Antioxidant and Anti-Inflammatory Effects",
    },
    {
      type: "paragraph",
      text: "Oxidative stress and inflammatory signaling are central to ischemia-reperfusion injury in cardiac tissue. Published research has documented reductions in malondialdehyde (MDA — a lipid peroxidation marker) and increases in superoxide dismutase (SOD) activity in cardiac tissue of Cortagen-treated rodents exposed to experimental ischemia. These findings parallel observations reported for other bioregulator peptides in their respective target tissues and suggest a broad cytoprotective phenotype rather than a highly specific pharmacological action.",
    },
    {
      type: "heading",
      text: "Key Research Areas and Published Findings",
    },
    {
      type: "paragraph",
      text: "Cortagen's published evidence base is primarily from preclinical rodent models and in vitro cell culture studies. Human clinical data is not available in the Western literature. Key published areas include:",
    },
    {
      type: "list",
      items: [
        "Ischemia-reperfusion cardioprotection: Reduced myocardial infarct size, decreased apoptosis markers, improved ejection fraction proxies in rat models",
        "Aging cardiac tissue: Modulation of gene expression profiles in aged cardiomyocytes; reduced markers of cellular senescence",
        "Cardiomyocyte survival in culture: Dose-dependent protection of isolated cardiomyocytes under hypoxic stress conditions",
        "Fibrosis attenuation: Reduced collagen content and TGF-β signaling in post-infarct remodeling models",
        "Antioxidant enzyme modulation: SOD, catalase, and glutathione peroxidase changes in cardiac homogenates",
      ],
    },
    {
      type: "callout",
      text: "Representative published work includes: Khavinson VKh et al., multiple publications in Bulletin of Experimental Biology and Medicine and Gerontology (2005–2018) documenting Cortagen effects in cardiac ischemia and aging models. The majority of these publications are accessible via PubMed with search terms: 'Cortagen peptide cardiac' or 'Ala-Glu-Asp-Pro cardioprotection'.",
    },
    {
      type: "heading",
      text: "Research Protocol Parameters",
    },
    {
      type: "table",
      headers: ["Parameter", "Typical Preclinical Value", "Notes"],
      rows: [
        ["Peptide sequence", "Ala-Glu-Asp-Pro (AEDP)", "Tetrapeptide; molecular weight ~430 Da"],
        ["Administration route", "Subcutaneous injection", "Primary route in published studies"],
        ["Dose range studied", "1–10 µg/kg (rodent)", "Ischemia model doses; aging studies may use different ranges"],
        ["Study duration", "14–30 days", "Chronic administration for aging endpoints; acute for ischemia"],
        ["Primary endpoints", "Infarct size, apoptosis markers, oxidative stress, fibrosis", "MDA, SOD, caspase-3, collagen quantification"],
        ["Species studied", "Rat (Wistar)", "Predominantly rat models; limited other species data"],
      ],
    },
    {
      type: "heading",
      text: "Cortagen in Context: Comparison with Other Cardioprotective Peptides",
    },
    {
      type: "paragraph",
      text: "Researchers studying peptide-mediated cardioprotection have several compounds to consider, each with distinct mechanisms. Understanding where Cortagen fits relative to more widely studied compounds is useful for research design:",
    },
    {
      type: "table",
      headers: ["Peptide", "Primary Mechanism", "Evidence Strength", "Regulatory Status"],
      rows: [
        ["Cortagen (AEDP)", "Transcriptional regulation, anti-apoptotic", "Preclinical — Russian research primarily", "Research use only (Western markets)"],
        ["SS-31 / Elamipretide", "Mitochondrial inner membrane stabilization, cardiolipin", "Strong preclinical; Phase II/III human trials", "IND status in USA"],
        ["BPC-157", "NO/VEGF upregulation, angiogenesis, GI-cardiac fistula models", "Strong preclinical", "Research use only"],
        ["Thymosin Beta-4 (TB-500)", "Actin dynamics, angiogenesis, cardiac progenitor recruitment", "Moderate preclinical; Phase I/II trials", "Research use only"],
        ["Hexarelin", "GHS-R1a agonism; direct cardiac receptor (CD36)", "Moderate preclinical", "Research use only"],
      ],
    },
    {
      type: "paragraph",
      text: "Cortagen occupies a unique position as a tissue-derived bioregulator with a proposed epigenetic mechanism. This makes it mechanistically complementary to compounds like SS-31 (mitochondria-targeted) or Hexarelin (receptor-acting) — potentially relevant for combination research protocols examining multiple cardioprotective pathways.",
    },
    {
      type: "heading",
      text: "Sourcing and Quality Verification",
    },
    {
      type: "paragraph",
      text: "Cortagen is a tetrapeptide with a well-defined chemical structure, accessible to synthesis via standard SPPS techniques. As with all research peptides, quality verification is critical for research validity. Key parameters for Cortagen research-grade material:",
    },
    {
      type: "list",
      items: [
        "HPLC purity ≥98%: Standard for research-grade short peptides; ensures that observed biological effects are attributable to Cortagen rather than process impurities",
        "Mass spectrometry verification: Confirm MW of ~430.41 Da (Ala-Glu-Asp-Pro); MALDI-TOF or ESI-MS both suitable",
        "Endotoxin testing: Essential for any injectable research administration; LAL assay (< 1.0 EU/mg)",
        "Sterile filtration: 0.22 µm for parenteral research use",
        "Lot-specific COA: From a third-party independent laboratory, not internal QC only",
      ],
    },
    {
      type: "heading",
      text: "Limitations of the Evidence Base",
    },
    {
      type: "list",
      items: [
        "Geographic concentration: The majority of published work comes from a small number of Russian research institutes, limiting independent replication by external groups",
        "No human clinical trials: All cardioprotective data is from preclinical animal models or cell culture",
        "Mechanism partially theoretical: The proposed transcriptional mechanism via histone interaction lacks the detailed structural characterization available for receptor-binding peptides",
        "Publication language: Some foundational studies are published in Russian-language journals and may not be fully indexed in English-language databases",
        "Dosing translation uncertainty: Rodent dose ranges cannot be directly extrapolated to other species without allometric scaling and additional validation",
      ],
    },
    {
      type: "paragraph",
      text: "These limitations should not necessarily deter research interest, but they do require that researchers approach Cortagen with appropriate scientific rigor — treating published findings as hypothesis-generating rather than conclusive, and designing studies with appropriate controls and validation endpoints.",
    },
    {
      type: "disclaimer",
      text: "All information presented is derived from published preclinical research and is intended for educational and research purposes only. Cortagen is not approved as a therapeutic agent in Western markets. Nothing in this article constitutes medical advice. All research use must comply with applicable institutional and regulatory requirements.",
    },
  ],
};
